HAVCR2 and neoplasm: Due to its critical function in inhibiting adaptive and innate immune responses, TIM-3 has been investigated in the context of anti-tumor immunity [22], and studies in animal models of cancer have shown that disruption of TIM-3 leads to a potentiation of endogenous anti-tumor immune responses [8, 10, 23].